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Abstract
Background: We are investigating a double transgenic rat (dTGR) model, in which rats transgenic
for the human angiotensinogen and renin genes are crossed. These rats develop moderately severe
hypertension but die of end-organ cardiac and renal damage by week 7. The heart shows necrosis
and fibrosis, whereas the kidneys resemble the hemolytic-uremic syndrome vasculopathy. Surface
adhesion molecules (ICAM-1 and VCAM-1) are expressed early on the endothelium, while the
corresponding ligands are found on circulating leukocytes. Leukocyte infiltration in the vascular wall
accompanies PAI-1, MCP-1, iNOS and Tissue Factor expression. Furthermore we show evidence
that Ang II causes the upregulation of NF-kB in our model.
Methods: We started PDTC-treatment on four weeks old dTGR (200 mg/kg sc) and age-matched
SD rats.. Blood-pressure- and albuminuria- measurements were monitored during the treatement
period (four weeks). The seven weeks old animals were killed, hearts and kidneys were isolated
and used for immunohistochemical-and electromobility shift assay analsis.
Results: Chronic treatment with the antioxidant PDTC decreased blood pressure (162 ± 8 vs. 190
± 7 mm Hg, p = 0.02). Cardiac hypertrophy index was significantly reduced (4.90 ± 0.1 vs. 5.77 ±
0.1 mg/g, p < 0.001) compared to dTGR. PDTC reduced 24 h albuminuria by 85 % (2.7 ± 0.5 vs.
18.0 ± 3.4 mg/d, p < 0.001) and prevented death significantly. Vascular injury was ameliorated in
small renal and cardiac vessels. PDTC inhibited NF-κ B binding activity in heart and kidney.
Immunohistochemical analysis shows increased expression of the p65 NF-κ B subunit in the
endothelium, smooth muscles cells of damaged small vessels, infiltrated cells, glomeruli, tubuli and
collecting ducts of dTGR. PDTC markedly reduced the immunoreactivity of p65.
Conclusion: Our data show that inhibition of NF-κ B by PDTC markedly reduces inflammation,
iNOS expression in the dTGR most likely leading to decreased cytotoxicity, and cell proliferation.
Thus, NF-κ B activation plays an important role in ANG II-induced end-organ damage.
Published: 18 January 2002
BMC Cardiovascular Disorders 2002, 2:3
Received: 13 September 2001
Accepted: 18 January 2002
This article is available from: http://www.biomedcentral.com/1471-2261/2/3
© 2002 Theuer et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, 
provided this notice is preserved along with the article's original URL.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/3
Page 2 of 12
(page number not for citation purposes)
Introduction
Hypertension injures blood vessels and thereby causes
end-organ damage. The mechanisms are complicated and,
although studied for decades in experimental animal
models, are only currently being elucidated [1] The en-
dothelial layer acts as a signal transduction interface for
hemo-dynamic forces in the regulation of vascular tone
and chronic structural remodeling of arteries. Effects of
mechanical forces on signal transduction and gene expres-
sion in endothelial cells have been demonstrated [2]. Mi-
crovascular endothelium in hypertensive animals has
been shown to exhibit increased oxyradical production at-
tributable to xanthine oxidase [3]. Oxyradical production
by endothelial cells can result in leukocyte-endothelial ad-
hesion responses that involve transcription-independent
and -dependent surface expression of different endotheli-
al cell adhesion molecules. Infiltration of the permeabi-
lized endothelium by leukocytes sets the stage for an
inflammatory cascade, involving cytokines, chemokines,
growth factors, and matrix metalloproteinases. Altered in-
tegrin signaling, the production of tenacin, epidermal
growth factor signaling, tyrosine phosphorylation, and ac-
tivation of downstream pathways culminate in vascular
smooth muscle cell proliferation. [4–6] Evidence is accu-
mulating that matrix molecules provide an environment
which decreases the rate of programmed cell death.
We have studied a double-transgenic rat model. The rats
harbor both the human renin and human angiotensino-
gen genes [7,8]. The rat and human renin-angiotensin sys-
tems do not interact, so the hypertension and
vasculopathy exhibited by these rats is the result of the
overexpression of the human renin-angiotensin system.
The rats were developed for the expressed purpose of stud-
ying human renin inhibitors that ordinarily do not func-
tion in rats. However, we have found that this model,
which features renal and cardiac failure by 8 weeks of age
in these animals, also provides great utility in studying
blood pressure-independent Ang II-related effects. To ex-
clude possible effects of blood pressure, we lowered blood
pressure with non-angiotensin-related hypotensive
agents. This strategy delayed morbidity and mortality by 1
week but did not ameliorate the inflammatory disease
process.
Many inflammation-mediating genes are activated by the
transcription factor NF-κ B, which resides inactive and
bound to the inhibitory protein I-κ B in the cytoplasm of
T lymphocytes, monocytes, macrophages, endothelial
cells, and smooth muscle cells [9]. ANG II stimulates
NADPH oxidase, which generates reactive oxygen species
(ROS) [10]. ROS may act as signal transduction messen-
gers for several important transcription factors, including
NF-κ B and AP-1 [11]. Several reports have indicated that
angiotensin converting enzyme (ACE) inhibition de-
creased NF-κ B in renal disease [12,13].
In vitro and in vivo studies showed that pyrrolidine dithi-
ocarbamate (PDTC) is a potent inhibitor of NF-κ B, but
had no effect on AP-1, CREB, Sp-1, and octamer-binding
proteins [14,15]. The precise mechanism for the biologi-
cal effects of PDTC is still controversial. Several studies
have reported that metal-chelating, thiol modifying and
oxygen radical-scavenging antioxidative properties medi-
ate the inhibition of NF-κ B [15]. We recently observed
that rats harboring both human renin and angiotensino-
gen genes (dTGR) develop severe renal and cardiac dam-
age, accompanied by increased NF-κ B DNA binding
activity, MCP-1 production, adhesion molecule expres-
sion, inflammation, and die by seven weeks of age
[16,17]. We now investigated the hypothesis that PDTC
inhibition of NF-κ B prevents inflammation and amelio-
rates cardiac and renal damage.
Material and Methods
Study design
Experiments were conducted in 4 week-old male dTGR
and age-matched SD rats. The dTGR line and characteris-
tics are described elsewhere1. The rats were purchased
from RCC (Füllinsdorf, CH), kept in rooms at 24 ± 2°C,
were fed with a standard rat diet containing 0.2% sodium
by weight, and were allowed free access to tap water. All
procedures were done according to guidelines from the
American Physiological Society and were approved by lo-
cal authorities (permit # G 408/97). In the first part of the
study we investigated 15 untreated dTGR and compared
them to 15 Sprague Dawley (SD) rats in the second part of
the study fifteen dTGR received PDTC (Sigma, Germany)
for 3 weeks once a day (200 mg/kg s.c.) [18,19], while 15
dTGR and 15 Sprague Dawley (SD) rats received vehicle
(0.9 % NaCl). Systolic blood pressure was measured
weekly by tail-cuff under light ether anesthesia 20 h after
the last drug dose. Urine samples were collected over a 24
h period. Urinary rat albumin was measured with a com-
mercially available ELISA (Celltrend, Germany). Rats were
killed at age 7 weeks. The kidneys and hearts were washed
with ice cold saline, blotted dry, and weighed. For electro-
phoretic mobility shift assay (EMSA) of NF-κ B and AP-1,
the tissues were snap-frozen in liquid nitrogen, for immu-
nohistochemistry in isopentane (-35°C), and stored at -
80°C.
Immunohistochemistry
Frozen kidneys and hearts were cryosectioned at 6 µm
thickness and air dried as described earlier [20,21]. The
sections were fixed with cold acetone, washed with TBS,
and incubated for 60 min in a humid chamber at room
temperature with primary monoclonal antibodies against
rat monocytes/macrophages (ED1, Serotec, England), NF-BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/3
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κ B subunit p65 (Roche Boehringer, Germany), ICAM-1,
VCAM-1, LFA-4, VLA-1 (1A29, R&D Systems, England)
and polyclonal inducible NO synthase (iNOS/NOS2)
(ABR, USA). After washing with TBS, the sections were in-
cubated with a bridging antibody (rabbit-anti-mouse IgG;
Dako, Germany) for 30 min at room temperature and
washed again with TBS. The APAAP-complex (Dako, Ger-
many) was applied and the sections were incubated for 30
min at room temperature. The immunoreactivity was vis-
ualized by development in a mixture of naphthol-AS-BI-
phosphate (Sigma, Germany) with neufuchsin (Merck,
Germany). Endogenous alkaline phosphatase was
blocked by addition of 10 mmol/L levamisole (Sigma,
Germany) to the substrate solution. The sections were
slightly counter stained in Mayer's haemalaun (Merck,
Germany), blued in a tap water, and mounted with GelTol
(Coulterimmunotech, Germany). Immunostaining was
performed as described earlier. Semiquantitative scoring
of ED-1 positive cells was performed using computerized
cell count program (KS 300 3.0, Zeiss, Germany). Fifteen
different areas of each heart and kidney samples (n = 5 in
all groups) were analyzed. The samples were examined
without knowledge of the rats' identity.
Electrophoretic mobility shift assay (EMSA)
Tissue extracts and EMSA for the transcription factor NF-
κ B were performed as described earlier [22,23]. Briefly,
frozen total kidneys were pulverized in liquid nitrogen
with a pestle and mortar, and resuspended in 3 mL 50
mmol/l Tris (pH 7.4) containing a complete inhibitor tab-
let (Roche Boehringer, Germany) and 1 mmol/l Na-ortho-
vanadate (Sigma Chemie, Germany). The suspension was
centrifuged (4000 g, 4 min, 4°C). The pellet was resus-
pended and lysed for 30 min in whole cell lysate buffer
(20 mmol/l Hepes pH 7.9, 350 mmol/l NaCl, 20% glycer-
ol, 1 mmol/l MgCl2, 0.5 mmol/l EDTA, 0.1 mmol/l EG-
TA, and 1% NP-40) and again centrifuged (13000 g, 10
min, 4°C). The supernatant was aliquoted and frozen in
liquid nitrogen at -80°C until use. The protein concentra-
tion for EMSA and Western blot was quantified by the
Bradford method. For EMSA, total renal homogenates (50
µg) were incubated in binding reaction medium (2 µg
poly dI-dC, 1 µg BSA, 1 mmol/l DTT, 20 mmol/l Hepes
pH 8.4, 60 mmol/l KCl and 8% Ficoll) with 0.5 ng of 32P-
dATP end-labeled oligonucleotide, containing the NF-κ B
binding site from the MHC-enhancer (H2K, 5'-gatcCAG-
GGCTGGGGATTCCCCATCTCCACAGG) at 30°C for 30
min. In competition assays 50 or 100 ng unlabeled H2K
oligonucleotides were used. For supershift assay, 1 µg of
anti-p50, anti-p65, anti-Rel B, and anti-c-Rel was added
20 min to the homogenates before addition of the labeled
probe. For AP-1 double-stranded oligonucleotides con-
Figure 1
Section from dTGR kidney stained with hematoxylin/eosin
and periodic acid-Schiff-stained section. Small vessels showed
increased intimal and medial thickness as well as hyaline
deposits, tubuls were swollen and filled with proteinaceous
material. Figure 2
Section from dTGR kidney stained with hematoxylin/eosin
and periodic acid-Schiff-stained section. Small vessels showed
increased intimal and medial thickness as well as hyaline
deposits, tubuls were swollen and filled with proteinaceous
material.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/3
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taining the consensus sequence for AP1 (Santa Cruz,
USA., 5'-GAT CGA ACT GAC CGC CCG CCG CCC GT-3')
were radiolabeled with γ -32P with the use of T4 polynu-
cleotide kinase by standard methods and purified over a
column. The DNA-protein complexes were analyzed on a
5% polyacrylamide gel 0,5% Tris buffer, dried and autora-
diographed. In competition assays 50 ng unlabeled H2K
or AP-1 oligonucleotides were used.
Statistical analysis
Data are presented as means ± SEM. Statistically signifi-
cant differences in mean values were tested by ANOVA
and the Tukey's multiple range test. A value of p < 0.05
was considered statistically significant. The data were ana-
lyzed using SYSTAT® statistical software (SYSTAT Inc,
Evanston, IL, USA).
Results
DTGR feature hypertension (190 ± 7 mm Hg vs 107 ± 2
mm Hg for SD at week 7, p < 0.001 n = 15, severe renal
damage, and focal necrosis in heart and kidney and a mor-
tality of 40 % at 7 weeks. Cardiac hypertrophy is one of
the leading features in dTGR (5,9 vs 3,6 heart weigth/body
weigth (mg/g). 24 h albuminuria progressively increased
in untreated dTGR from 5 to 7 weeks. (57.1 ± 8.7 vs. 0.3 ±
Figure 3
Representative immunohistochemical photomicrograph of
PAI-1 and Fibronectin in the heart of dTGR. PAI-1 and
fibronectin expression were increased in the perivascular
space and adventitia of dTGR compared to SD.
Figure 4
Representative immunohistochemical photomicrograph of
PAI-1 and Fibronectin in the heart of dTGR. PAI-1 and
fibronectin expression were increased in the perivascular
space and adventitia of dTGR compared to SD.
Figure 5
Representative immunohistochemical photomicrograph of
PAI-1 and Fibronectin in the heart of dTGR.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/3
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0.1 mg/d week 7). Small vessels showed increased intimal
and medial thickness as well as hyaline deposits, tubuls
were swollen and filled with proteinaceous material (Fig.
1 and 2). PAI-1 and fibronectin expression were increased
in the perivascular space and adventitia of dTGR com-
pared to SD (Fig. 3,4,5,6).
There was significant infiltration in cardiac and renal
perivascular space of dTGR compared to SD. Fig. 7 and 8
show a representative immunohistochemistry for ED1, a
marker for macophages in the heart and in the kidney (9
and 10). Fig. 24 shows semiquantative scoring for macro-
phage-monocyte-infiltration of ED-1 in the kidney and in
the heart. This was perforned using a computerized cell
count programm.
The expression ot the adhesion protein VCAM-1 was in-
creased in the interstitium, intima and adventitia of the
small renal and cardiac vessels in dTGR compared to SD
animals (Fig. 11,12,13,14). Similar results were obtained
for ICAM-1 (see below). The counterreceptors for ICAM-1
and VCAM-1, α Lβ 2 integrin (LFA-1) and α 4β 1 (VLA-4)
were upregulated in the perivascular space and the adven-
titia of the heart (Fig. 15 and 16) and the kidney (Fig. 17
and 18) in dTGR compared to SD.
A schematic diagram in Fig. 19 summarizes the Ang II sig-
naling in the dTGR model, resulting in oxidative stress,
participation of endothelin, and transcription factor acti-
vation. These transcription factors activate a host of genes
involved in inflammation including surface adhesion
molecules, thrombogenic factors, chemokines, and induc-
ible NO synthase
Subsequently, we used the dTGR model for a pharmaco-
logical intervention with PDTC to prevent NF-κ B signal-
ling. In week 7 mortality was reduced to 0%, cardiac
hypertrophy reduced to 4.90 ± 0.1 (vs. 5.77 ± 0.1 mg/g, p
< 0.001), albuminuria to 2.5 ± 0.8 mg/d and blood pres-
sure to 162 ± 8 mm Hg, respectively. ICAM-1 expression
in the kidney was increased in the intima, adventitia, and
in the perivascular space of the small vessels in untreated
dTGR. Glomeruli and tubules also showed increased
ICAM-1 expression. Expression of ICAM-1 was markedly
reduced by treatment with PDTC and was similar to the
Figure 6
Representative immunohistochemical photomicrograph of
PAI-1 and Fibronectin in the heart of SD.
Figure 7
Representative immunohistochemical photomicrograph of
ED-1 in the heart of dTGR.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/3
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constitutive ICAM-1 expression in control animals at
week 7 (Fig. 20a,b,c). Furthermore we showed significant-
ly reduced macrophage-monocyte-infiltration in the kid-
ney and in the heart by semiquantative cell count analysis
(Fig. 24) in PDTC treated rats compared to untreated
dTGR (6 ± 1 vs. 22 ± 1, p < 0.0001). These results demon-
strate that PDTC treatment reduced mononuclear cell in-
filtration and inhibited the expression of adhesion
molecules.
Next, we investigated the effects of PDTC on iNOS expres-
sion. We observed a strong increase in iNOS expression in
the glomeruli in the vessel walls of renal arterioles (Fig.
21d,e,f). Treatment with PDTC greatly reduced the iNOS
immunoreactivity both in the blood vessels and the
glomeruli. Furthermore, we investigated the activation of
the transcription factor NF-κ B, which is one of the main
regulator of ICAM-1 and iNOS gene expression. Immuno-
histochemistry (phase contrast resolution) shows the lo-
calization of the subunit p65 of NF-κ B in a cardiac vessel.
The p65 expression was increased in the endothelium,
smooth muscle cells (Fig. 22), as well as in the vessel wall,
infiltrated cells, glomeruli, and tubules (data not shown)
of dTGR kidneys. PDTC markedly reduced p65 expression
(Fig. 22). No immunoreaction was observed in non-trans-
genic SD rats (Fig. 22). The antibody recognizes an
epitope overlapping the nuclear location signal of p65
subunit and therefore selectively stains released, activated
NF-κ B after dissociation from its inhibitor Iκ Ba [24]. We
used EMSA for the detection of NF-κ B DNA binding activ-
ity in the kidney (Fig. 23A) and heart (Fig. 23D). NF-κ B
DNA binding activity in the kidney was markedly reduced
by PDTC treatment and even more in the heart. Each lane
represents a separate animal. Renal homogenates were in-
cubated with antibodies against the NF-κ B subunits anti-
p50, anti-p65, anti-c-Rel, and anti-Rel B (23 B). Binding
specificity was demonstrated by competition of excess un-
Figure 8
Representative immunohistochemical photomicrograph of
ED-1 in the heart of SD animals.
Figure 9
Representative immunohistochemical photomicrograph of
ED-1 in the kidney of dTGR.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/3
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labeled oligonucleotides containing the kB site from the
MHC-enhancer (H2K) (23 C). AP-1 activity was increased
in dTGR kidneys compared with SD (data not shown).
However, PDTC treatment did not reduce AP-1 binding
activity (data not shown).
Discussion
As the growing role of "oxidative stress" in the pathogen-
esis of hypertension becomes more appreciated, our im-
pression of hypertension as a rather indolent, solely
hemo-dynamic process is being revised [25]. Reactive ox-
ygen species are the end result of univalent reductions in
oxygen, resulting in the production of superoxide anion,
hydrogen peroxide, and water. Reactive oxygen species in-
fluence both normal and abnormal cellular processes, in-
cluding cellular growth, hypertrophy, remodeling, lipid
oxidation, modulation of vascular tone, and inflamma-
tion [26]. Reactive oxygen species can also act as intracel-
lular signaling molecules in vascular cells controlling
growth, survival, and apoptosis [4]. An important source
of reactive-oxygen species are the NADH/NADPH oxidas-
es, which are regulated in part by Ang II [10]. Touyz and
Schiffrin recently showed that in vascular smooth muscle
cells from human peripheral resistance arteries, Ang II in-
Figure 10
Representative immunohistochemical photomicrograph of
ED-1 in the kidney of SD animals.
Figure 11
Representative immunohistochemical photomicrograph of
VCAM-1 in the heart of dTGR.
Figure 12
Representative immunohistochemical photomicrograph of
VCAM-1 in the heart of SD animals.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/3
Page 8 of 12
(page number not for citation purposes)
creased H2O2 generation through phospholipase D-de-
pendent, NADH/NADPH oxidase-sensitive pathways
[27]. A role for reactive oxygen species in Ang II-mediated
transcription factor activation has been established. The
potential targets of reactive oxygen species in endothelial
and vascular smooth muscle cells are extracellular signal-
related kinases, stress-activated protein kinases, caspases,
and NF-κ B [4]. NF-κ B activation has been associated with
vascular inflammation [28]. The activation of NF-κ B in-
volves the phosphorylation and subsequent proteolytic
degradation of the inhibitory protein Iκ B by specific Iκ B
Figure 13
Representative immunohistochemical photomicrograph of
VCAM-1 in the kidney of dTGR.
Figure 14
Representative immunohistochemical photomicrograph of
VCAM-1 in the kidney of SD animals.
Figure 15
Representative immunohistochemical photomicrograph of
LFA-1 in the heart of dTGR.
Figure 16
Representative immunohistochemical photomicrograph of
LFA-1 in the heart of SD animals.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/3
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kinases. The free NF-κ B, a heterodimer consisting of 2 pro-
teins, p50 and p65, passes into the nucleus, where it binds
to kB sites in the promoter region of numerous genes in-
Figure 17
Representative immunohistochemical photomicrograph of
VLA-4 in the kidney of dTGR.
Figure 18
Representative immunohistochemical photomicrograph of
VLA-4 in the kidney of SD animals.
Figure 19
Schematic diagram of Ang II signaling in the dTGR model.
Figure 20
Representative immunohistochemical photomicrographs of
ICAM-1 in the kidney of dTGR (a), PDTC treated dTGR (b),
and SD rats (c). The expression of ICAM-1 was increased in
the intima, adventitia and in the perivascular space of the
small dTGR vessels. Glomeruli and tubuli showed frequently
increased ICAM-1 expression.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/3
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volved in inflammation [29]. Many of these genes code
for cytokines, chemokines, enzymes, proteins involved in
coagulation, receptors, protein-ases, and adhesion mole-
cules. These molecules contribute to the alterations in
structure and mechanical properties responsible for the
remodeling of resistance arteries in hypertension [30].
We tested the hypothesis that inhibition of NF-κ B pre-
vents inflammatory responses and ameliorates cardiac
and renal damage. We found that NF-κ B inhibition pre-
vented inflammatory responses, ameliorated cardiac and
renal damage, and reduced mortality completely. Chronic
PDTC treatment decreased blood pressure and cardiac
hypertrophy slightly, but reduced albuminuria almost
completely. The modest decrease in blood pressure was
probably related to amelioration of renal failure rather
than the result of a vasodilator effect.
We showed earlier that ANG II production in the kidneys
and elsewhere is responsible for this severe vasculopathy
[31]. ANG II stimulates various signaling pathways lead-
ing to NF-κ B activation. PDTC is a potent inhibitor of NF-
Figure 21
Panel d-f show a representative immunohistochemical phot-
omicrographs of iNOS in the kidney. iNOS expression was
increased in glomeruli and the vessel wall of dTGR. PDTC
reduced the iNOS expression.
Figure 22
Immunohistochemical analysis of the subunit p65 of NF-κ B in
the heart of dTGR show a increased expression in the
endothelial cells and smooth muscles cells in the vessel wall,
which was partially reduced by PDTC.
Figure 23
Effects of PDTC on the activation of DNA binding nuclear
factors in the kidney (A) and heart (D). EMSA for the detec-
tion of NF-κ B shows a higher binding activity of dTGR kidney
and heart homogenates compared with SD rats. NF-κ B DNA
binding activity in the kidney was markedly reduced by PDTC
treatment and even more in the heart. Each lane represents a
separate animal. Renal homogenates were incubated with
antibodies against the NF-κ B subunits anti-p50, anti-p65,
anti-c-Rel, and anti-Rel B (B). Specificity of binding (C) was
demonstrated by competition of excess unlabeled oligonucle-
otides containing the kB site from the MHC-enhancer (H2K).
EMSA was performed 3 times independently with similar
results.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/3
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κ B [32]. Schreck et al. and Liu et al. demonstrated that
PDTC inhibited NF-κ B activation of various stimulants,
but had no effect on AP-1, CREB, Sp-1, and octamer-bind-
ing proteins in several cell lines and in vivo [14,15]. In our
study, PDTC markedly decreased NF-κ B binding activity
in the heart and kidney, while AP-1 was not decreased.
Nakamura et al. found that administration of antioxi-
dants inhibited cardiac hypertrophy [33]. In our model,
chronic treatment with PDTC partially reduced cardiac
hypertrophy.
NF-κ B plays a central role in various cardiovascular diseas-
es. Ruiz-Ortega et al. reported that NF-κ B activation and
MCP-1 expression in the renal cortex was reduced by ACE
inhibition in experimental immune complex nephritis
[13]. Morrissey and Klahr showed that ACE inhibition de-
creased NF-κ B in kidneys with ureteral obstruction [34].
Recently, Rangan et al. demonstrated that NF-κ B inhibi-
tion by PDTC reduced inflammation and tubulointersti-
tial injury in nonimmune proteinuric rats [19].
Myocardial and renal reperfusion injury develops to a
large extent subsequent to the complex interaction of
multiple cytokines and activated adhesion molecules
[20,35,36]. Morishita et al. demonstrated that NF-κ B inhi-
bition by a decoy technique reduced the extent of myocar-
dial infarction following reperfusion [36]. Hernandez-
Presa have shown that ACE inhibition prevents arterial
NF-κ B activation, chemokine expression, and macro-
phage infiltration in early accelerated atherosclerosis [12].
We performed immunohistochemical analysis for NF-κ B
subunit p65, because in contrast to the p50 subunit, p65
contains the transcription activation domain. The anti-
body recognizes an epitope overlapping the nuclear loca-
tion signal of p65 subunit and therefore selectively stains
released activated NF-κ B after dissociation from its inhib-
itor Iκ Bα  [24]. The NF-κ B subunit p65 was increased in
the endothelium, smooth muscles cells of damaged small
vessels, and infiltrated cells in dTGR. The staining pattern
resembled the localization of the p65 expression in
atherosclerotic lesions.
Untreated dTGR show a 150-fold increased albuminuria.
Remuzzi and coworkers demonstrated that increased
glomerular permeability is followed by increased filtra-
tion of macromolecules, followed by excessive tubular
protein reabsorption [37,38]. This process leads to abnor-
mal accumulation of proteins in endolysosomes and en-
doplasmatic reticulum. Altogether, these processes foster
the activation of NF-κ B dependent and independent cy-
tokines resulting in renal inflammation. Chronic inhibi-
tion of NF-κ B by PDTC probably inhibited both the direct
activation of NF-κ B by ANG II as well as the subsequent
activation induced by the increased glomerular permea-
bility in our model, thereby breaking the self-amplifying
loop.
We also examined inducible NO synthase (iNOS). Pro-
moter deletion and mutation studies in cultured cells
demonstrated that NF-κ B plays a critical role in transcrip-
tional regulation of the iNOS gene induced by various cy-
tokines [39] NO regulates numerous physiological and
pathophysiological processes, including smooth muscle
contractility, platelet reactivity, and the cytotoxic activity
of leukocytes. However, inappropriate release of this me-
diator has been linked to the pathogenesis of a number of
disease states [40]. While endothelial NO serves beneficial
roles as a messenger and host defense molecule, excessive
NO production by inducible NOS can be cytotoxic. In-
deed, peroxynitrite anion formation, protein tyrosine ni-
tration, and hydroxyl radical production may contribute
to the evolution of several commonly encountered renal
diseases, including postischemic renal failure, obstructive
nephropathy, and renal allograft rejection, among others
[41]. Our data show that inhibition of NF-κ B by PDTC
markedly reduces inflammation, iNOS expression in the
dTGR most likely leading to decreased cytotoxicity, and
cell proliferation. Thus, NF-κ B activation plays an impor-
tant role in ANG II-induced end-organ damage.
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